Physician profile
Dave E Webster
NPI 1992808018
$2,698.24
in general payments reported to CMS, 2019-2025
26 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $476 · 2021: $182 · 2022: $416 · 2023: $486 · 2024: $288 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,113.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $641.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $321.70 | 2022-2024 | |
| Glaxosmithkline, LLC. | $255.95 | 2020-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $220.56 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Allergan, INC. | $206.29 | 2019-2020 | |
| Pfizer INC. | $172.53 | 2019-2025 | |
| Abbott Laboratories | $144.84 | 2019-2025 | Proclaim |
| Astrazeneca Pharmaceuticals Lp | $93.97 | 2020-2024 | Airsupra |
| Novartis Pharmaceuticals Corporation | $86.00 | 2021-2022 | |
| Abbvie INC. | $72.13 | 2019-2022 | |
| Amgen INC. | $67.48 | 2019-2025 | Otezla, Repatha, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $53.61 | 2019-2021 | |
| Medtronic, INC. | $50.65 | 2023 | Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $49.94 | 2020-2022 | |
| Exact Sciences Corporation | $35.90 | 2023-2024 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.00 | 2023-2024 | Xifaxan |
| Amarin Pharma, INC. | $31.54 | 2019 | |
| Arbor Pharmaceuticals, INC. | $29.41 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $24.03 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.57 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.46 | 2022 | |
| Nevro Corp. | $18.69 | 2023 | Senza |
| Spinal Simplicity, LLC | $15.58 | 2025 | Ha Minuteman G3-R |
| Biohaven Pharmaceuticals, INC. | $12.93 | 2021 | |
| Shire North American Group INC | $11.11 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dave Webster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.